Get the Stockscreener App
99.74
0.02%
0.02
After Hours:
99.74
Lantheus Holdings Inc stock is traded at $99.74, with a volume of 846.97K.
It is up +0.02% in the last 24 hours and down -1.12% over the past month.
Lantheus Holdings Inc is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver patient outcomes. The Company classifies its products into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Its products help healthcare professionals Find, Fight and Follow cancer and diseases and are used by physicians and technologists in clinical settings. The Company produces and markets its products in the United States, mainly to hospitals, independent imaging centers and government facilities, and sells outside the United States through direct and third-party distribution relationships and licensing arrangements in Europe, Canada, Australia, Asia-Pacific, Central America and South America.
See More
Previous Close:
$99.72
Open:
$99.92
24h Volume:
846.97K
Relative Volume:
0.65
Market Cap:
$6.51B
Revenue:
$1.54B
Net Income/Loss:
$233.56M
P/E Ratio:
29.62
EPS:
3.3669
Net Cash Flow:
$348.64M
1W Performance:
-0.81%
1M Performance:
-1.12%
6M Performance:
+31.88%
1Y Performance:
+93.78%
1-Day Range:
$99.72
$99.99
1-Week Range:
$99.69
$100.96
52-Week Range:
$49.67
$111.86
Lantheus Holdings Inc Stock (LNTH) Company Profile
Name
Lantheus Holdings Inc
Sector
Phone
978 671-8001
Address
331 TREBLE COVE ROAD, NORTH BILLERICA, MA
Compare LNTH vs TAK, TEVA, HLN, ZTS, VTRS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LNTH
Lantheus Holdings Inc
|
99.74 | 6.51B | 1.54B | 233.56M | 348.64M | 3.3669 |
TAK
Takeda Pharmaceutical Co Adr
|
18.86 | 60.23B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
39.19 | 45.71B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.26 | 40.72B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
71.05 | 29.36B | 9.51B | 2.64B | 2.14B | 6.0361 |
VTRS
Viatris Inc
|
17.83 | 20.48B | 14.57B | -296.50M | 1.64B | -0.259 |
Lantheus Holdings Inc Stock (LNTH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-26-26 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-12-25 | Upgrade | Truist | Hold → Buy |
| Oct-08-25 | Downgrade | Goldman | Buy → Neutral |
| Aug-12-25 | Downgrade | Truist | Buy → Hold |
| Dec-18-24 | Initiated | Goldman | Buy |
| Sep-03-24 | Initiated | Redburn Atlantic | Buy |
| Jul-10-24 | Reiterated | JMP Securities | Mkt Outperform |
| Dec-18-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Dec-04-23 | Initiated | TD Cowen | Outperform |
| Sep-29-23 | Initiated | William Blair | Outperform |
| Mar-08-23 | Initiated | JMP Securities | Mkt Outperform |
| Nov-30-22 | Initiated | SVB Leerink | Outperform |
| Oct-13-22 | Initiated | Mizuho | Buy |
| May-09-22 | Initiated | B. Riley Securities | Buy |
| Apr-13-22 | Initiated | Truist | Buy |
| Feb-01-21 | Initiated | SVB Leerink | Outperform |
| Jun-29-20 | Resumed | Jefferies | Buy |
| Aug-16-19 | Upgrade | CJS Securities | Market Perform → Market Outperform |
| Nov-02-17 | Upgrade | Wells Fargo | Market Perform → Outperform |
| Nov-08-16 | Reiterated | RBC Capital Mkts | Outperform |
| Sep-23-16 | Resumed | Credit Suisse | Neutral |
| Feb-24-16 | Reiterated | RBC Capital Mkts | Outperform |
| Dec-11-15 | Downgrade | Credit Suisse | Outperform → Neutral |
| Sep-30-15 | Downgrade | Wells Fargo | Outperform → Market Perform |
| Jul-20-15 | Initiated | Credit Suisse | Outperform |
| Jul-20-15 | Initiated | Jefferies | Buy |
| Jul-20-15 | Initiated | RBC Capital Mkts | Outperform |
| Jul-20-15 | Initiated | Robert W. Baird | Outperform |
| Jul-20-15 | Initiated | Wells Fargo | Outperform |
View All
Lantheus Holdings Inc Stock (LNTH) Latest News
Lantheus Holdings (LNTH) Could Be 7% Undervalued On BRAVNETSA Approval - finance.yahoo.com
Lantheus Holdings (LNTH) Stock May Be 14% Undervalued On FDA Approval - finance.yahoo.com
Lantheus stock trades at USD 99.72 after FDA approval - AD HOC NEWS
FDA approves Lantheus’ Bravnetsa for GEP-NETs - DOTmed
FDA approval for Lantheus’ Bravnetsa - The Pharma Letter
Lantheus Holdings, Inc. (LNTH) Stock Forecasts - Yahoo! Finance Canada
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Werewolf Therapeutics, Inc. (Nasdaq – HOWL), Beazer Homes USA, Inc. (NYSE – BZH), Lantheus Holdings Inc. (Nasdaq – LNTH), MarketAxess Holdings Inc. ( - The Daily Tribune News
Curium Resets FTC Clock On $8B Lantheus Take-Private Deal - Law360
After selling nearly 1.4 million shares in one day, a Perspective Therapeutics (CATX) holder still has a stake. - Stock Titan
LNTH Stock Drops After-Hours As Curium's $7B Offer Comes In Below Market Value - Stocktwits
Strong Earnings, FDA Approval, and Takeover Interest Drive Lantheus Holdings’ (LNTH) Rally - finance.yahoo.com
3 Reasons LNTH is Risky and 1 Stock to Buy Instead - finance.yahoo.com
Lantheus Holdings wins FDA approval for Bravnetsa before Curium vote - Mugglehead Investment Magazine
Lantheus wins final FDA approval for BRAVNETSA (lutetium Lu 177 dotatate( for GEP-NETs - app.dealroom.co
LNTH Looks 11.3% Overvalued on GF Value™ After FDA Approval - GuruFocus
Lantheus Holdings, Inc. Receives Final FDA Approval for BRAVNETSA for Treatment of GEP-NETs - marketscreener.com
Lantheus Says Curium Resubmits Antitrust Filing for Merger - Moomoo
FDA approves Lantheus’ BRAVNETSA for neuroendocrine tumors By Investing.com - Investing.com Australia
FDA approves Lantheus’ BRAVNETSA for neuroendocrine tumors - Investing.com India
Lantheus Receives Final FDA Approval for BRAVNETSA™ (Lutetium Lu 177 Dotatate), the Only Radiopharmaceutical FDA has Determined to be Bioequivalent and Therapeutically Equivalent to LUTATHERA® for the Treatment of GEP-NETs - marketscreener.com
A radioactive cancer treatment becomes the first approved through the FDA’s abbreviated drug pathway - Stock Titan
The Technical Signals Behind (LNTH) That Institutions Follow - Stock Traders Daily
Lantheus Holdings stock faces a new Curium review window - AD HOC NEWS
LNTH Looks 11.3% Overvalued on GF Value™ - GuruFocus
Lantheus Holdings, Inc. (LNTH) Stock Analysis: A Healthcare Powerhouse with a 7.15% Potential Upside - DirectorsTalk Interviews
Lantheus Holdings, Inc. (LNTH): Investor Outlook On A Potential 7.47% Upside - DirectorsTalk Interviews
(LNTH) Risk Channels and Responsive Allocation - Stock Traders Daily
LNTH, ITGR and CZR Deals Face Investor Scrutiny - stl.news
Lantheus Holdings Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Lantheus Holdings, Inc.LNTH - Business Wire
Perspective Therapeutics (CATX) Insider Sale: 10% Owner Lantheus Alpha Therapy, LLC Sells 247,932 Shares - GuruFocus
Perspective Therapeutics (CATX) holder sells stock near $3.10 - Stock Titan
Lantheus Alpha Therapy Sells 113,914 Perspective Therapeutics (AMEX: CATX) Shares at Up to $3.14 Per Share - Kalkine Media
Lantheus Entities Hold 20.9% Stake in Radiopharm Theranostics (NASDAQ: RADX) Including Significant Options - Kalkine Media
Lantheus Group Reduces Stake in Perspective Therapeutics (AMEX: CATX) to 10% Amid Activist 13D Filing - Kalkine Media
Lantheus Holdings (NASDAQ: LNTH) 10% Stakeholder Alpha Therapy Sells 42,129 Shares at $3.11 Each - Kalkine Media
Lantheus (NASDAQ: LNTH) holders to vote on cash buyout with potential bonus payout - Stock Titan
Radioligand Therapy Market to Grow from USD 2.98 Billion in 2025 to USD 15.85 Billion by 2035, at a CAGR of 18.2% - GlobeNewswire Inc.
Lantheus Holdings, Inc. (LNTH) Stock Analysis: Exploring Growth Potential in the Healthcare Sector - DirectorsTalk Interviews
Lantheus alpha therapy, CATX director, sells $131k in stock By Investing.com - Investing.com Australia
Lantheus alpha therapy, CATX director, sells $131k in stock - Investing.com
Perspective Therapeutics (CATX) Insider Sell: 10% Owner Lantheus Alpha Therapy, LLC Disposes of 42,129 Shares - GuruFocus
Lantheus Holdings (NASDAQ: LNTH) Disposes of 35,769 Perspective Therapeutics Shares at $3.12 Each - kalkinemedia.com
Perspective Therapeutics (CATX) backer trims stake but keeps 11.5M shares - Stock Titan
10% owner of Perspective Therapeutics (NYSE: CATX) sells 113,914 shares over two days - Stock Titan
Perspective Therapeutics (CATX) backer Lantheus now owns 10% after share sales - Stock Titan
Perspective Therapeutics Inc (CATX) Insider Sell: 10% Owner Holdings, Lantheus Disposes of 35,769 Shares - GuruFocus
Perspective Therapeutics (CATX) holder sells 35K shares, still owns 11.6M - Stock Titan
Lantheus Holdings sells $245,609 in Perspective Therapeutics stock By Investing.com - Investing.com India
Perspective Therapeutics Inc (CATX) Insider Sell: 10% Owner Holdings, Lantheus Disposes of 78,145 Shares - GuruFocus
Lantheus Holdings sells $245,609 in Perspective Therapeutics stock - Investing.com
Technical Reactions to LNTH Trends in Macro Strategies - Stock Traders Daily
Lantheus Holdings Inc Stock (LNTH) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.18%
0.69%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):